Navigation Links
Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director
Date:1/9/2012

SHENZHEN, China, Jan. 9, 2012 /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ("Global Pharm" or the "Company"), a growing vertically integrated pharmaceutical company engaged in the distribution of pharmaceutical-related products, Traditional Chinese Medicine ("TCM") processing, and herbal cultivation and sales in China through its subsidiaries in Anhui, Jilin, Guangdong and Shandong provinces, today announced the appointment of Mr. Kwong Chi Wong (Simon) as a non-executive director to its Board of Directors (the "Board"), effective January 4, 2012. The Board increased the size of the Board from five to six directors on January 4, 2012 and appointed Mr. Wong to fill the vacancy.  Currently, three of the Board members are independent directors, one is a non-executive director and two are executive directors.

Mr. Wong brings more than three decades of experience in investing and assisting companies in China. Since March 5, 2010, Mr. Wong has been executive director and chief executive officer of China.com Inc. (HKEX 8006). Mr. Wong served as a director of CDC Corporation, the ultimate holding company of China.com Inc., until September 2011. Mr. Wong is also a director and chief executive officer of CDC Games Corporation and a director of CDC Games International Corporation, both of which are subsidiaries of CDC Corporation.

Mr. Wong was a managing partner of Asian Global Capital ("AGC"). Prior to joining AGC, he was a director and executive vice president of Transpac Capital Ltd. ("Transpac"), one of the earliest and largest private equity investment firms in Asia, managing a $820 million portfolio with investments in approximately 200 companies in East Asia and the United States. Prior to joining Transpac, Mr. Wong was deputy managing director of Cony Electronics Products Ltd. and Hung Nien Electronics Ltd. in Hong Kong and president of Cony Electronics Inc. in Chicago. Mr. Wong also serves on the boards of various Hong Kong listed companies and holds leadership positions in various Hong Kong financial and industrial associations and councils. Mr. Wong received Bachelor of Science and MBA degrees from the Chinese University of Hong Kong.

"We are excited to add Mr. Kwong Chi Wong (Simon) to our newly enhanced board," said Mr. Yunlu Yin, Chairman and Chief Executive Officer of Global Pharm. "Simon's comprehensive understanding of the financial markets and extensive experience of investment and operational management in numerous companies add a distinctive knowledge base and comprehensive business network to our board. The expansion of Global Pharm's Board of Directors ensures that the company will continue to benefit from a diversity of experience and opinions."

About Global Pharm

Global Pharm Holdings Group, Inc., a growing integrated pharmaceutical company, is engaged in the distribution of pharmaceutical-related products, Traditional Chinese Medicine (TCM) processing, and herbal cultivation and sales in China. The Company focuses on building regional distribution channels, as well as a local capillary sales network with a high-margin product portfolio. Currently, its sales network covers Shandong, Jilin, Anhui and Guangdong provinces. Global Pharm seeks to establish an integrated value chain in the pharmaceutical industry through strategic acquisitions within the TCM production, pharmaceutical distribution and retail sectors. For further information, please visit the Company's corporate website at http://www.globalpharmholdings.com.

Forward-looking Statements

Certain statements set forth in this press release contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made by our management. Such statements reflect the current view of our management with respect to future events and are subject to risks, uncertainties, assumptions and other factors as they relate to our industry, our operations and results of operations, plans for future facilities, capital-expenditure plans and any businesses that we may acquire. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the U.S. federal securities laws, we do not intend to update any of the forward-looking statements to conform them to actual results.

For Additional Information Contact

Global Pharm Holdings Group, Inc.
Ms. Susan Liu
Phone: +86-755-3693-9373
Email: susanliu@globalpharmholdings.com


'/>"/>
SOURCE Global Pharm Holdings Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MarketsandMarkets: Global Healthcare BPO Market worth $330 Billion by 2016
2. Global Pharma Selects Semantellis Compliance Ready Social Listening Platform to Manage Corporate Reputation
3. Ikaria® Commences Global Registration Trial for Bioabsorbable Cardiac Matrix
4. Marken Appoints New Head of Global Quality Assurance
5. Cardium and SourceOne Global Partners Enter Into Cross-Strategic Equity Investment with Plans to Jointly Develop Nutritional Supplements and Medical Foods
6. Global Markets for Laser Systems, Components and Materials -- Focus on Asia-Pacific
7. Pulmonary Drug Delivery Systems: Technologies and Global Markets
8. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
9. MD+DI, the Global MedTech Industry Authority, Highlights the Human Element in Medical Device Design: Designing the Devices Surgeons Want and Pushing the Boundaries of Innovation
10. Medical Device Costa Rica: An MPO Symposium Helps Firms Connect, Learn & Master Global Manufacturing Skills
11. Global In Vitro Diagnostic Market Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition ... muscular dystrophy, and funding for Duchenne research, participated in the April 25 U.S. ... Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in ...
(Date:4/29/2016)... ... 29, 2016 , ... The Society for Assisted Reproductive Technology ... required to report in vitro fertilization (IVF) delivery rates to both ... of assisted reproductive technologies in the United States. , This year, SART’s ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... The ... the workforce is aging – meaning that there is an urgent need for highly ... and interactive training solution, delivering a multi-pronged approach to train and retain care managers, ...
Breaking Medicine News(10 mins):